Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Tenalisib (RP6530), a dual phosphoinositide 3-kinase δ/γ inhibitor was evaluated in a phase I/Ib study for maximum tolerated dose (MTD), pharmacokinetics, and efficacy in patients with relapsed/refractory peripheral and cutaneous T-Cell Lymphoma (TCL). Histologically confirmed (TCL) patients, with ≥...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Huen, Auris, Haverkos, Bradley M., Zain, Jasmine, Radhakrishnan, Ramchandren, Lechowicz, Mary Jo, Devata, Sumana, Korman, Neil J., Pinter-Brown, Lauren, Oki, Yasuhiro, Barde, Prajak J., Nair, Ajit, Routhu, Kasi Viswanath, Viswanadha, Srikant, Vakkalanka, Swaroop, Iyer, Swaminathan P.
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7463651/
https://ncbi.nlm.nih.gov/pubmed/32824175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12082293
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars